Anterogen.Co.,Ltd.
Financials
Valuation Metrics
Anterogen.Co.,Ltd.'s Market Cap is ₩1502B. At end of 2025 it was ₩4688B. Ranked #1014 of 2,421 in KR market (top 42%), #513 of 1,640 on KOSDAQ (top 31%), #116 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 50%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 150.19B KRW | KR#1,014/2,421 Sec#116/231 |
| Revenue | 8.37B KRW | KR#2,303/2,421 Sec#181/231 |
| Net Income | -1.62B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 88.26B KRW | KR#1,878/2,421 Sec#152/231 |
| Net Assets | 87.45B KRW | KR#1,509/2,421 Sec#119/231 |
| Employees | 29 | KR#2,209/2,421 Sec#206/231 |
| Value | ||
| P/B | 1.72x | KR#1,847/2,421 Sec#135/231 |
| P/S | 17.95x | KR#2,331/2,421 Sec#182/231 |
| FCF Yield | -0.74% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -1.85% | KR#1,679/2,421 Sec#117/231 |
| ROA | -1.83% | KR#1,739/2,421 Sec#123/231 |
| Op. Margin | -29.40% | KR#2,176/2,421 Sec#154/231 |
| Revenue Growth | 16.55% | KR#638/2,421 Sec#59/231 |
| Financial Health | ||
| Debt Ratio | 0.93% | KR#3/2,421 Sec#2/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | -1.12B KRW | KR#1,286/2,421 Sec#97/231 |
| Cash | 1.58B KRW | KR#2,286/2,421 Sec#216/231 |
| Performance | ||
| 1Y Return | -36.67% | KR#1,754/2,421 Sec#144/231 |
| 1M Return | -1.77% | KR#1,451/2,421 Sec#110/231 |
| From 52W High | -75.71% | KR#2,299/2,421 Sec#204/231 |
| 1Y MDD | -74.41% | KR#2,158/2,421 Sec#190/231 |
| Trading | ||
| Volume | 21,802 shares | KR#1,550/2,421 Sec#153/231 |
| Trading Value | 327.5M KRW | KR#1,094/2,421 Sec#112/231 |
| Foreign Own. | 4.25% | KR#991/2,421 Sec#89/231 |
| Per Share | ||
| EPS | -162 KRW | KR—/2,421 Sec—/231 |
| BPS | 8,739 KRW | KR#1,074/2,421 Sec#73/231 |
Company Info
Antrogen, established in 2000 and listed on KOSDAQ in 2016, is a specialized stem cell therapy bio-venture. In 2012, it gained the world's first marketing approval for Cupistem, an adipose-derived stem cell product for Crohn's fistula, and holds exclusive domestic sales rights for pulmonary hypertension treatments Remodulin and Tyvaso. Through its diverse disease pipeline, Antrogen is expanding its business and strengthening its competitive edge in rare and intractable disease treatments. It is headquartered in Geumcheon-gu, Seoul.